Drug Type Small molecule drug |
Synonyms JNJ 16241199, JNJ-16241199, R 306465 + [1] |
Target |
Action inhibitors |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors), Epigenetic drug |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H19N5O4S |
InChIKeyMUTBJZVSRNUIHA-UHFFFAOYSA-N |
CAS Registry604769-01-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Sep 2005 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Sep 2005 |
Phase 1 | 15 | wgvpfghleq(isewawbozi) = approximately 5-10 fold increase over baseline in 2 patients dosed at 400 mg omkjjakvdm (ijizibbhac ) | - | 20 Jun 2007 |





